GHP Investment Advisors Inc. Raises Stock Holdings in Stryker Co. (NYSE:SYK)

GHP Investment Advisors Inc. boosted its position in Stryker Co. (NYSE:SYK) by 0.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 37,618 shares of the medical technology company’s stock after purchasing an additional 305 shares during the period. GHP Investment Advisors Inc.’s holdings in Stryker were worth $13,545,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Oakworth Capital Inc. boosted its holdings in Stryker by 3.9% during the 4th quarter. Oakworth Capital Inc. now owns 6,104 shares of the medical technology company’s stock valued at $2,198,000 after acquiring an additional 230 shares during the period. Silver Oak Securities Incorporated purchased a new stake in Stryker in the fourth quarter worth $571,000. Adero Partners LLC increased its stake in shares of Stryker by 5.4% in the 4th quarter. Adero Partners LLC now owns 801 shares of the medical technology company’s stock worth $288,000 after acquiring an additional 41 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Stryker in the 4th quarter worth approximately $139,000. Finally, Bleakley Financial Group LLC raised its stake in Stryker by 25.2% during the fourth quarter. Bleakley Financial Group LLC now owns 9,763 shares of the medical technology company’s stock valued at $3,515,000 after buying an additional 1,964 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada boosted their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $419.37.

Stryker Stock Performance

NYSE SYK opened at $399.01 on Thursday. The stock’s 50 day simple moving average is $377.08 and its 200-day simple moving average is $364.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market cap of $152.11 billion, a PE ratio of 51.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 EPS. As a group, equities research analysts anticipate that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.84%. Stryker’s payout ratio is 43.30%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.